MY147921A - Proteasome inhibitors and methods of using the same - Google Patents

Proteasome inhibitors and methods of using the same

Info

Publication number
MY147921A
MY147921A MYPI20060567A MYPI20060567A MY147921A MY 147921 A MY147921 A MY 147921A MY PI20060567 A MYPI20060567 A MY PI20060567A MY PI20060567 A MYPI20060567 A MY PI20060567A MY 147921 A MY147921 A MY 147921A
Authority
MY
Malaysia
Prior art keywords
methods
same
proteasome inhibitors
compositions
proteasome activity
Prior art date
Application number
MYPI20060567A
Other languages
English (en)
Inventor
Ambrogio Oliva
Rafaella Bernardini
Germano D Arasmo
Paolo G Cassara
Alberto Bernareggi
Ernesto Menta
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MY147921A publication Critical patent/MY147921A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MYPI20060567A 2005-02-11 2006-02-10 Proteasome inhibitors and methods of using the same MY147921A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65237005P 2005-02-11 2005-02-11
US11/351,193 US7468383B2 (en) 2005-02-11 2006-02-09 Proteasome inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
MY147921A true MY147921A (en) 2013-02-15

Family

ID=36579482

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20060567A MY147921A (en) 2005-02-11 2006-02-10 Proteasome inhibitors and methods of using the same

Country Status (19)

Country Link
US (2) US7468383B2 (enExample)
EP (1) EP1846424B1 (enExample)
JP (1) JP2008530108A (enExample)
AT (1) ATE456571T1 (enExample)
AU (1) AU2006213814B2 (enExample)
CA (1) CA2597273C (enExample)
CY (1) CY1109985T1 (enExample)
DE (1) DE602006012013D1 (enExample)
DK (1) DK1846424T3 (enExample)
ES (1) ES2339698T3 (enExample)
IL (1) IL184678A (enExample)
MX (1) MX2007009664A (enExample)
MY (1) MY147921A (enExample)
NZ (1) NZ560607A (enExample)
PL (1) PL1846424T3 (enExample)
PT (1) PT1846424E (enExample)
SI (1) SI1846424T1 (enExample)
TW (1) TWI367886B (enExample)
WO (1) WO2006086600A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
UA101303C2 (uk) 2006-06-19 2013-03-25 Протеолікс, Інк. Сполуки для інгібування ферменту протеасоми
EP2044055A4 (en) * 2006-07-21 2011-03-23 Takeda Pharmaceutical amide compounds
CN105837608B (zh) * 2007-08-06 2018-06-08 米伦纽姆医药公司 蛋白酶体抑制剂及其组合物和用途
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
EP2212334B1 (en) * 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
SG194349A1 (en) 2008-06-17 2013-11-29 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions thereof
NZ590887A (en) * 2008-08-04 2012-09-28 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
JP2013518046A (ja) 2010-01-25 2013-05-20 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
CA2791651C (en) * 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
EP3243515B1 (en) 2011-08-30 2019-10-16 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490279A1 (ru) 2011-08-30 2014-08-29 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
US9493439B1 (en) 2014-04-07 2016-11-15 University Of Kentucky Research Foundation Proteasome inhibitors
AU2015243346C9 (en) * 2014-04-08 2019-03-07 Abliva Ab Novel cell-permeable succinate compounds
CR20160577A (es) 2014-05-20 2017-01-06 Millennium Pharm Inc Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria
PE20170770A1 (es) 2014-07-17 2017-07-04 Chdi Foundation Inc Metodos y composiciones para tratar trastornos relacionados con vih
KR102547709B1 (ko) * 2017-02-28 2023-06-23 치아타이 티안큉 파마수티컬 그룹 주식회사 아제티딘 유도체
GB201808149D0 (en) 2018-05-18 2018-07-11 Univ Court Univ Of Glasgow Protected amino acids
AU2019315561B2 (en) * 2018-08-02 2024-01-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Borate of azetidine derivative

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301354A1 (de) 1983-01-18 1984-07-19 Matth. Hohner Ag, 7218 Trossingen Elektronisches musikinstrument
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
IL97428A0 (en) 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
WO1994017816A1 (en) 1993-02-10 1994-08-18 The President And Fellows Of Harvard College Role of atp-ubiquitin-dependent proteolysis in mhc-1 restricted antigen presentation and inhibitors thereof
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
JP3486412B2 (ja) 1993-04-30 2004-01-13 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2170104T3 (es) 1993-10-01 2002-08-01 Merrell Pharma Inc Inhibidores de la produccion de proteinas de beta-amiloide.
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
EA001915B1 (ru) 1996-10-18 2001-10-22 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) * 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
JP2002508321A (ja) * 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
GB9806815D0 (en) * 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
CN1331752A (zh) 1998-10-20 2002-01-16 千年药物公司 监测蛋白酶体抑制剂药物作用的方法
EP1053750A1 (en) 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
CA2370830C (en) 1999-04-27 2009-10-13 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
WO2001020995A1 (en) 1999-09-23 2001-03-29 Washington University Compounds directed against pilus biogenesis and activity in pathogenic bacteria; methods and compositions for synthesis thereof
EP1477180A1 (en) 1999-10-20 2004-11-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
ATE338564T1 (de) 2000-10-12 2006-09-15 Viromics Gmbh Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
EP2251344B2 (en) * 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
IL158136A0 (en) 2001-04-09 2004-03-28 Method for identification of proteins from intracellular bacteria
US7214769B2 (en) 2001-05-23 2007-05-08 The Curators Of The University Of Missouri Method for inverse solid phase synthesis of peptides
CN100415770C (zh) 2001-05-30 2008-09-03 诺瓦提斯公司 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
KR100399359B1 (ko) * 2001-07-07 2003-09-26 삼성전자주식회사 전하 펌프 회로
AU2002324734A1 (en) 2001-08-16 2003-03-03 Levente Fabry-Asztalos Borinic acid protease inhibitors
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
AU2003219652A1 (en) * 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2005016659A1 (ja) 2003-08-13 2005-02-24 Seiko Precision Inc. カードの製造方法及びカード製造装置
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
NZ582693A (en) 2007-08-06 2012-01-12 Millennium Pharm Inc Boron-containing proteasome inhibitors

Also Published As

Publication number Publication date
ES2339698T3 (es) 2010-05-24
JP2008530108A (ja) 2008-08-07
AU2006213814B2 (en) 2011-10-13
CA2597273C (en) 2013-12-17
TW200640936A (en) 2006-12-01
US7468383B2 (en) 2008-12-23
DE602006012013D1 (de) 2010-03-18
TWI367886B (en) 2012-07-11
EP1846424A1 (en) 2007-10-24
WO2006086600A1 (en) 2006-08-17
CA2597273A1 (en) 2006-08-17
US20090075936A1 (en) 2009-03-19
IL184678A (en) 2012-05-31
ATE456571T1 (de) 2010-02-15
SI1846424T1 (sl) 2010-05-31
US20060189806A1 (en) 2006-08-24
MX2007009664A (es) 2007-09-26
IL184678A0 (en) 2007-12-03
NZ560607A (en) 2009-11-27
HK1106534A1 (en) 2008-03-14
PT1846424E (pt) 2010-04-15
DK1846424T3 (da) 2010-05-17
US8283367B2 (en) 2012-10-09
AU2006213814A1 (en) 2006-08-17
EP1846424B1 (en) 2010-01-27
PL1846424T3 (pl) 2010-06-30
CY1109985T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
IL184678A0 (en) Proteasome inhibitors and methods of using the same
PH12012501372B1 (en) Proteasome inhibitors and methods of using the same
WO2005016859A3 (en) Proteasome inhibitors and methods of using the same
PH12014500053A1 (en) Proteasome inhibitors
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2012037155A3 (en) Tyrosine kinase inhibitors
MX340186B (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY162518A (en) Proteasome inhibitors and methods of using the same
MY180594A (en) Proteasome inhibitors